In 2019, an indirect comparison meta-analysis evaluated the efficacy of pembrolizumab alone versus pembrolizumab combined chemotherapy for the first-line treatment of advanced NSCLC patients with PD-L1 TPS of ≥50%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.